Compare AbbVie Inc (ABBV) vs Duolingo Inc (DUOL) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

Duolingo (DUOL) trades at $131.95, up 4.92% with strong technical momentum and bullish moving average signals. The company demonstrates exceptional fundamental strength with 2025 revenue reaching $1.04 billion and net income of $414 million, representing a 38.4% margin. Recent earnings beats and expanding profitability highlight operational excellence amid AI-driven product expansion into math and music learning.

Outlook remains positive with projected 2026 revenue growth to $1.1 billion, though the stock trades above analyst consensus target of $110.20. Key risks include competitive pressure in edtech and valuation concerns with P/E of 14.8 and P/S of 5.7. Institutional sentiment leans cautious with 59% hold ratings despite strong fundamentals.